This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Align Technology's Management Presents At Morgan Stanley Healthcare Conference - Transcript

Align Technology, Inc (ALGN)

Align Technology at Morgan Stanley Healthcare Conference

September 11, 2012 08:00 AM ET


Kenneth Arola - Vice President, Finance and Chief Financial Officer


Steve Beuchaw - Morgan Stanley


Steve Beuchaw - Morgan Stanley

Good morning everyone. Thank you for joining us. I am Steve Beuchaw from the Morgan Stanley Medtech team. It is my pleasure to have you all here and to introduce Align Technology. We have Ken Arola, CFO of the company.

Before we begin though, please do note that all important disclosures including all personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at It’s a riveting read. So Ken, I would like to open the floor to you for any opening remarks.

Kenneth Arola

Sure. I just like to thank everybody for being this morning at Morgan Stanley Conference, just a little bit of Align Technology for those of you who don’t know. We have been in business for about 12 to 13 years as a public company. We’ve helped about 2 million patients get treatment and generated over about $2 billion in revenue over that time period along the way was delivering about 75 to 80 million individual class II medical devices which we call aligners.

Our strategy for the company really focuses around four key areas. One of them being clinical innovation giving doctors what they want to treat the patient effectively and get the results that they are looking for and I am sure we’ll get some questions on that at this morning. The other one is the driving consumer demand and educating patients so they can walk into doctor’s offices understanding the capabilities of what Align – Invisalign can do for them and should basically challenge a doctor if that something they want as a formal treatment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,832.33 +112.41 0.63%
S&P 500 2,095.95 +15.54 0.75%
NASDAQ 5,143.5040 +34.8380 0.68%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs